Related Experiment Videos
Pathogenesis of malignant mesothelioma
Michele Carbone1, Monica A Rdzanek
1Cancer Immunology Program, Department of Pathology, Cardinal Bernardin Cancer Center, Loyola University Chicago, Maywood, IL 60153, USA. mcarbon@orion.it.luc.edu
Clinical Lung Cancer
|May 1, 2004
Summary
Malignant mesothelioma (MM) is a cancer linked to asbestos exposure and Simian virus 40 (SV40). Genetic predisposition combined with erionite fiber exposure also causes MM in specific regions.
Area of Science:
- Oncology
- Environmental Health
- Virology
Background:
- Malignant mesothelioma (MM) is an aggressive cancer strongly associated with asbestos exposure.
- The specific roles of different asbestos types, exposure levels, and mechanisms of asbestos-induced tumorigenesis remain under investigation.
- Simian virus 40 (SV40) and genetic factors, particularly in combination with erionite fibers in Cappadocia, Turkey, are also implicated in MM etiology.
Purpose of the Study:
- To review the established and debated factors contributing to malignant mesothelioma (MM) development.
- To highlight the roles of asbestos, SV40, and genetic predispositions in MM.
- To discuss diagnostic methods and current therapeutic limitations for MM.
Main Methods:
- Review of epidemiological studies and scientific literature on MM.
- Analysis of the etiological contributions of asbestos, SV40, and genetic factors.
- Description of diagnostic techniques including histology, electron microscopy, and immunohistochemistry.
Main Results:
- Asbestos is a primary cause of MM, though specific fiber types and exposure thresholds are debated.
- Simian virus 40 (SV40) large T antigen and small t antigen are implicated in viral carcinogenicity, potentially acting as cocarcinogens with asbestos.
- A genetic predisposition interacting with erionite exposure in Cappadocia, Turkey, leads to a high incidence of MM.
Conclusions:
- Multiple factors including asbestos, SV40, and genetic predisposition contribute to MM development.
- Current MM therapies offer limited survival benefits.
- Development of an SV40 vaccine may help reduce MM incidence in high-risk populations like asbestos workers.